Viridian Therapeutics, Inc. (VRDN)
30.87
+0.39
(+1.28%)
USD |
NASDAQ |
Nov 13, 16:00
31.02
+0.15
(+0.49%)
After-Hours: 07:56
Viridian Therapeutics Enterprise Value : 2.889B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 2.889B |
| November 12, 2026 | 2.845B |
| November 11, 2026 | 2.932B |
| November 10, 2026 | 2.888B |
| November 09, 2026 | 2.812B |
| November 06, 2026 | 2.619B |
| November 05, 2026 | 2.626B |
| November 04, 2026 | 2.683B |
| November 03, 2026 | 2.240B |
| November 02, 2026 | 2.257B |
| October 30, 2026 | 2.185B |
| October 29, 2026 | 2.200B |
| October 28, 2026 | 2.140B |
| October 27, 2026 | 2.120B |
| October 26, 2026 | 2.034B |
| October 23, 2026 | 1.924B |
| October 22, 2026 | 1.975B |
| October 21, 2026 | 1.997B |
| October 20, 2026 | 1.931B |
| October 19, 2026 | 1.746B |
| October 16, 2026 | 1.545B |
| October 15, 2026 | 1.605B |
| October 14, 2026 | 1.471B |
| October 13, 2026 | 1.453B |
| October 12, 2026 | 1.462B |
| Date | Value |
|---|---|
| October 09, 2026 | 1.503B |
| October 08, 2026 | 1.467B |
| October 07, 2026 | 1.460B |
| October 06, 2026 | 1.453B |
| October 05, 2026 | 1.542B |
| October 02, 2026 | 1.587B |
| October 01, 2026 | 1.541B |
| September 30, 2026 | 1.722B |
| September 29, 2026 | 1.624B |
| September 28, 2026 | 1.689B |
| September 25, 2026 | 1.677B |
| September 24, 2026 | 1.699B |
| September 23, 2026 | 1.786B |
| September 22, 2026 | 1.864B |
| September 21, 2026 | 1.803B |
| September 18, 2026 | 1.851B |
| September 17, 2026 | 1.843B |
| September 16, 2026 | 1.900B |
| September 15, 2026 | 1.831B |
| September 14, 2026 | 1.873B |
| September 11, 2026 | 1.765B |
| September 10, 2026 | 1.883B |
| September 09, 2026 | 1.933B |
| September 08, 2026 | 1.983B |
| September 04, 2026 | 1.955B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Travere Therapeutics, Inc. | 4.990B |
| Arrowhead Pharmaceuticals, Inc. | 6.959B |
| Vertex Pharmaceuticals, Inc. | 136.71B |
| TG Therapeutics, Inc. | 10.00B |
| ACADIA Pharmaceuticals, Inc. | 2.335B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -101.21M |
| Revenue (Quarterly) | 25.75M |
| Total Expenses (Quarterly) | 126.96M |
| EPS Diluted (Quarterly) | -0.8924 |
| Gross Profit Margin (Quarterly) | 92.74% |
| Profit Margin (Quarterly) | -393.0% |
| Earnings Yield | -13.53% |
| Normalized Earnings Yield | -13.70 |